6533b856fe1ef96bd12b2504

RESEARCH PRODUCT

Programmed colorectal cancer screening decreases incidence and mortality

Andrés CervantesSoraya SimónSusana Roselló

subject

Oncologymedicine.medical_specialtyColorectal cancerlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicine030212 general & internal medicineneoplasmsHepatologymedicine.diagnostic_testbusiness.industryMortality rateIncidence (epidemiology)Fecal occult bloodGastroenterologyCancerSigmoidoscopymedicine.diseasedigestive system diseasesEndoscopy030220 oncology & carcinogenesisbusiness

description

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer- related deaths in the world (1). Detecting and removing precancerous lesions or detecting tumors in early stages through endoscopy decreases CRC mortality (2). Randomized controlled trials (RCTs) have shown that CRC screening based on guaiac fecal occult blood testing (gFOBT) and flexible sigmoidoscopy is effective in reducing incidence and mortality rates of CRC (3).

yearjournalcountryeditionlanguage
2019-12-01Translational Gastroenterology and Hepatology
https://doi.org/10.21037/tgh.2019.12.13